Prognostic significance of serum tumor markers in various pathologic subtypes of gastric cancer

J Gastrointest Surg. 2024 May;28(5):694-702. doi: 10.1016/j.gassur.2024.02.023. Epub 2024 Feb 20.

Abstract

Purpose: This study aimed to assess the utility of 6 serum tumor markers in prognosis between gastric adenocarcinoma and gastric signet ring cell carcinoma (SRCC).

Methods: A cohort of 3131 cases of gastric adenocarcinoma and 275 cases of gastric SRCC was assembled. The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125, alpha fetoprotein (AFP), carbohydrate antigen 242 (CA242), and carbohydrate antigen 724 (CA724) were measured in all cases. The study analyzed the association between the levels of these 6 tumor markers and the prognosis of gastric adenocarcinoma and SRCC.

Results: The study revealed that gastric SRCC exhibited lower concentrations of CEA (P < .001) and CA19-9 (P = .002), along with reduced positive rates of CEA (P = .041), CA19-9 (P = .003), AFP (P < .001), and CA242 (P = .006), while displaying higher positive rates of CA724 (P = .024) than gastric adenocarcinoma. Nevertheless, the receiver operating characteristic curve demonstrated that serum tumor markers did not hold clinical significance in differentiating between gastric adenocarcinoma and SRCC. Survival analysis substantiated that the combined criteria of serum tumor markers stood as an independent risk factor for both gastric adenocarcinoma and SRCC. Notably, the nomogram indicated that serum tumor markers exerted a more substantial influence on the prognosis of gastric adenocarcinoma than on gastric SRCC.

Conclusion: The study concluded that the combined criteria of serum tumor markers emerge as independent risk factors for both subtypes of gastric cancer. Furthermore, this combined approach exhibited enhanced efficacy in prognosticating the outcome of gastric adenocarcinoma compared with gastric SRCC.

Keywords: Gastric adenocarcinoma; Gastric cancer; Gastric signet ring cell carcinoma; Prognosis; Serum tumor markers.

MeSH terms

  • Adenocarcinoma* / blood
  • Adenocarcinoma* / mortality
  • Adenocarcinoma* / pathology
  • Adult
  • Aged
  • Antigens, Tumor-Associated, Carbohydrate* / blood
  • Biomarkers, Tumor* / blood
  • CA-125 Antigen / blood
  • CA-19-9 Antigen* / blood
  • Carcinoembryonic Antigen* / blood
  • Carcinoma, Signet Ring Cell* / blood
  • Carcinoma, Signet Ring Cell* / mortality
  • Carcinoma, Signet Ring Cell* / pathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms* / blood
  • Stomach Neoplasms* / mortality
  • Stomach Neoplasms* / pathology
  • alpha-Fetoproteins* / analysis
  • alpha-Fetoproteins* / metabolism

Substances

  • Biomarkers, Tumor
  • alpha-Fetoproteins
  • CA-19-9 Antigen
  • Carcinoembryonic Antigen
  • Antigens, Tumor-Associated, Carbohydrate
  • CA-72-4 antigen
  • CA 242 antigen
  • CA-125 Antigen